Heat shock-peptide complex vaccine as adjuvant therapy for high-risk patients with resected renal cell carcinoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
Skinner D, Colvin R, Vermillion C, et al.: Diagnosis and management of renal cell carcinoma: a clinical and pathologic study of 309 cases. Cancer 1971, 28:1165–1177.
Motzer R, Mazumdar M, Bacik J, et al.: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530–2540.
Fleischman J, Alyskewycz M, Flanigan R: Stage III renal cell carcinoma: staging subcategories and prognosis. Presented at the American Urological Association Annual Meeting. New Orleans: April 10–12, 1997.
Zisman A, Pantuck A, Wieder J, et al.: Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002, 20:4559–4566.
Clark J, Atkins M, Urba W, et al.: Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine workshop group randomized trial. J Clin Oncol 2003, 21:3133–3140.
Hoos A, Levey D: Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications. Expert Rev Vaccines 2003, 2:369–379.
Old L, Boyse E, Clarke D, et al.: Antigenic properties of chemically induced tumors. Ann NY Acad Sci 1962, 101:80.
Srivastava P, DeLeo A, Old L: Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci U S A 1986, 83:3407–3411.
Janetzki S, Blachere NE, Srivastava PK: Generation of tumorspecific cytotoxic T lymphocytes and memory T cells by immunization with tumor-derived heat shock protein gp96. J Immunother 1998, 21:269–276.
Wang X, Kazim I, Repasky E, et al.: Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccination activity. J Immunol 2001, 166:490–497.
Nicchitta C: Biochemical, cell biological, and immunological issues surrounding the endoplasmic reticulum chaperone GRP94/gp96. Curr Opin Immunol 1998, 10:103–109.
Yedavelli S, Guo L, Daou M, et al.: Preventive and therapeutic effect of tumor-derived heats shock protein, gp 96, in an experimental prostate cancer model. Int J Mol Med 1999, 4:243–248.
Tamura Y, Peng P, Daou M, et al.: Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997, 278:117–120.
Assikis V, Daliani D, Pagliaro C, et al.: Phase II study of an autologous tumor-derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma (mRCC) [Abstract 1552]. Proc Am Soc Clin Oncol 22:386.